Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial
Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial
复制标题
DOI：
10.1111/1756-185x.12333
复制
发表时间：
2014-06-01
影响因子：
2.5
通讯作者：
Mohtadi-Nia, Javad
中科院分区：
文献类型：
--
作者：
Alipour, Beitullah;Homayouni-Rad, Aziz;Mohtadi-Nia, Javad
目的：本研究旨在探讨补充干酪乳杆菌01对女性类风湿关节炎（RA）症状和炎症生物标志物的影响。方法：在这项随机双盲临床试验中，年龄在20-80岁，体重指数（BMI）低于40的女性RA患者在补充前稳定用药3个月，随机分配接受含有10(8)菌落形成单位（CFU）的乳杆菌01胶囊或安慰剂8周；按BMI和绝经状态分层分配。计算疾病活动性评分-28 (DAS28)，评估欧洲抗风湿病联盟（EULAR）的反应，并测量细胞因子、白细胞介素(IL)-1 β、IL-6、IL-10、IL-12和肿瘤坏死因子(TNF)- α。结果：每组30例；益生菌组和安慰剂组分别分析了22名和24名患者。添加干酪乳杆菌01降低了血清高敏c反应蛋白（hs-CRP）水平、关节压痛和肿胀计数、GH评分和DAS28 （P < 0.05）。在研究结束时，基于EULAR标准，L. casei 01组中更多的患者对治疗有中等反应（P < 0.01）。研究结束时，两组在整个研究过程中IL-10、IL-12和tnf - α的变化差异有统计学意义（P < 0.05），益生菌组优于对照组。无不良反应的干预报告。结论：补充益生菌可能是RA患者适当的辅助治疗，有助于缓解症状和改善炎症细胞因子。
Aim: The present study aimed at investigating the effects of Lactobacillus casei 01 supplementation on symptoms and inflammatory biomarkers of rheumatoid arthritis (RA) in women.Method: In this randomized double-blind clinical trial, female patients with established RA for more than 1 year, 20-80 years of age and body mass index (BMI) lower than 40, who followed stable medication for 3 months prior to the supplementation, were randomly allocated to receive either one capsule containing 10(8) colony forming units (CFU) of L. casei 01, or a placebo for 8 weeks; allocation was stratified by BMI and menopausal status. Disease activity score-28 (DAS28) was calculated, European League Against Rheumatism (EULAR) response was evaluated and the cytokines, interleukin (IL)-1 beta, IL-6, IL-10, IL-12 and tumor necrosis factor (TNF)-alpha were measured.Results: Thirty patients were recruited in each group; 22 and 24 patients were analyzed in the probiotic and placebo groups, respectively. L. casei 01 supplementation decreased serum high-sensitivity C-reactive protein (hs-CRP) levels, tender and swollen joint counts, global health (GH) score and DAS28 (P < 0.05). More patients in the L. casei 01 group had moderate response to the treatment, based on the EULAR criteria, at the end of the study (P < 0.01). At the end of the study, a significant difference was observed between the two groups for IL-10, IL-12 and TNF-alpha changes through the study course (P < 0.05), in favor of the probiotic group. No adverse effects were reported for the intervention.Conclusion: Probiotic supplementation may be an appropriate adjunct therapy for RA patients and help alleviate symptoms and improve inflammatory cytokines.